Almirall S.A. (ALM) - Total Liabilities
Based on the latest financial reports, Almirall S.A. (ALM) has total liabilities worth €882.40 Million EUR (≈ $1.03 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Almirall S.A. - Total Liabilities Trend (2003–2024)
This chart illustrates how Almirall S.A.'s total liabilities have evolved over time, based on quarterly financial data. See Almirall S.A. (ALM) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Almirall S.A. Competitors by Total Liabilities
The table below lists competitors of Almirall S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sixt SE
XETRA:SIX2
|
Germany | €5.15 Billion |
|
5N Plus Inc.
TO:VNP
|
Canada | CA$302.32 Million |
|
AIMA Technology Group Co Ltd
SHG:603529
|
China | CN¥14.61 Billion |
|
Tianjin Guangyu Development Co Ltd
SHE:000537
|
China | CN¥68.27 Billion |
|
Par Pacific Holdings Inc
NYSE:PARR
|
USA | $2.66 Billion |
|
Autobio Diagnostics Co Ltd
SHG:603658
|
China | CN¥2.88 Billion |
|
BBB Foods Inc.
NYSE:TBBB
|
USA | $22.83 Billion |
|
VGP NV
BR:VGP
|
Belgium | €2.54 Billion |
Liability Composition Analysis (2003–2024)
This chart breaks down Almirall S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ALM market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Almirall S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Almirall S.A. (2003–2024)
The table below shows the annual total liabilities of Almirall S.A. from 2003 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €908.28 Million ≈ $1.06 Billion |
-0.36% |
| 2023-12-31 | €911.59 Million ≈ $1.07 Billion |
+9.97% |
| 2022-12-31 | €828.98 Million ≈ $969.16 Million |
-3.12% |
| 2021-12-31 | €855.71 Million ≈ $1.00 Billion |
-13.40% |
| 2020-12-31 | €988.15 Million ≈ $1.16 Billion |
-14.79% |
| 2019-12-31 | €1.16 Billion ≈ $1.36 Billion |
-3.19% |
| 2018-12-31 | €1.20 Billion ≈ $1.40 Billion |
+14.86% |
| 2017-12-31 | €1.04 Billion ≈ $1.22 Billion |
-19.68% |
| 2016-12-31 | €1.30 Billion ≈ $1.52 Billion |
+21.36% |
| 2015-12-31 | €1.07 Billion ≈ $1.25 Billion |
-10.92% |
| 2014-12-31 | €1.20 Billion ≈ $1.40 Billion |
+35.78% |
| 2013-12-31 | €884.39 Million ≈ $1.03 Billion |
+104.51% |
| 2012-12-31 | €432.44 Million ≈ $505.57 Million |
-28.15% |
| 2011-12-31 | €601.89 Million ≈ $703.68 Million |
-16.10% |
| 2010-12-31 | €717.40 Million ≈ $838.72 Million |
-1.99% |
| 2009-12-31 | €732.00 Million ≈ $855.78 Million |
-47.58% |
| 2008-12-31 | €1.40 Billion ≈ $1.63 Billion |
+61.35% |
| 2007-12-31 | €865.45 Million ≈ $1.01 Billion |
+146.60% |
| 2006-12-31 | €350.96 Million ≈ $410.31 Million |
+15.50% |
| 2005-12-31 | €303.85 Million ≈ $355.23 Million |
-9.74% |
| 2004-12-31 | €336.66 Million ≈ $393.59 Million |
-2.41% |
| 2003-12-31 | €344.96 Million ≈ $403.30 Million |
-- |
About Almirall S.A.
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism; antiinfecti… Read more